On September 22, President Donald Trump and HHS secretary Robert Kennedy Jr publicly claimed a link between prenatal use of acetaminophen (marketed as Tylenol in the US) and autism.
Speaking in the Roosevelt Room at the White House, Trump warned: ‘With Tylenol, don’t take it! Don’t take it’. He added that the FDA would begin notifying doctors that the use of acetaminophen ‘can be associated’ with an increased risk of autism.
Secretary Kennedy described the move as ‘the first FDA-recognized treatment pathway, informing doctors and families about potential risks, and investing in groundbreaking research’.
Kenvue, the parent company of Tylenol, responded in a statement: ‘We believe independent, sound science clearly shows that taking acetaminophen does not cause autism.’
Medical experts and professional societies quickly pushed back. According to Dr Amanda Fleischman of the American College of Obstetricians and Gynecologists: ‘Not a single reputable study has successfully concluded that the use of acetaminophen in any trimester of pregnancy causes neurodevelopmental disorders in children.’
Moreover, Arthur Caplan of the New York University School of Medicine’s Division of Medical Ethics labelled the claims as ‘unsupported and wrong,’ further describing them as ‘flat out malpractice in managing pregnancy and protecting fetal life’.
Despite this professional rejection, the announcement’s political backing and visibility have elevated the issue beyond scientific debate and into the legal and regulatory arenas. For general counsel (GC) and chief legal officers (CLOs) in the medical industry, the implications are potentially significant.
Appeals in limbo
One of the immediate legal concerns is the potential resurrection of previously dismissed litigation related to Tylenol and autism. Over 500 lawsuits were consolidated in multidistrict litigation but dismissed by Judge Denise Cote in 2024, largely because the plaintiffs’ expert testimony was deemed unreliable and therefore inadmissible.
However, the plaintiffs’ lawyer Ashley Keller earlier this week filed a letter urging the Second Circuit Court of Appeals to reconsider that dismissal considering the Trump administration’s public statements. Keller argued that Dr Andrea Baccarelli, the same expert excluded at trial, now effectively has official backing, which warrants reconsideration of the expert evidence.
Under the Securities Act of 1933 and the Securities Exchange Act of 1934, public companies must disclose material risks that could impact their business or stock price. Failure to do so can lead to shareholder litigation and regulatory scrutiny.
Moreover, companies marketing acetaminophen or over-the-counter pain relief may face questions about whether their SEC filings adequately disclosed the risk of autism litigation or regulatory action. The announcement from the current administration amplifies these risks as what may have been considered speculative could now meet the threshold of ‘reasonably possible’ or ‘reasonably likely’ for disclosures.
As a result, GC and CLOs should engage securities counsel to review and potentially update risk factors in Forms 10-K and 10-Q, assessing whether the public changes and evolving science warrant enhanced disclosure.
Labelling as a legal trigger
In product liability litigation, companies may face increased scrutiny on whether their warnings and labelling adequately address emerging risks. The Food, Drug and Cosmetic Act enables the FDA to mandate labelling changes or safety communications when new evidence suggests a health risk.
Should the FDA align with the administration’s position as indicated and require changes to acetaminophen labelling, this would likely affect ongoing and future litigation, as plaintiffs argue that previous warnings were inadequate.
If this extends to other branches of government such as Congress, it could potentially result in amendments to the FDCA or new reform laws expanding manufacturer obligations regarding post-market safety monitoring and risk disclosures.
Although the Tylenol-autism controversy is unlikely to trigger liability immunity under statutes like the Public Readiness and Emergency Preparedness Act, which covers emergency medical countermeasures, the political spotlight may prompt legislative initiatives to limit liability exposure for over-the-counter drugs amid evolving scientific uncertainty.
Other statutes, such as the Biomaterials Access Assurance Act of 1998, offer limited protections to suppliers of raw components from product liability claims. While not directly applicable, these frameworks demonstrate potential legislative avenues for safe havens or exclusions in response to these litigation threats.
Looking ahead
While scientific consensus on acetaminophen and autism remains unresolved, political voices are already reshaping the regulatory and litigation environment. In this evolving landscape, GC and CLOs in FDA-regulated industries face renewed legal exposure, even in cases previously dismissed.
To protect their organizations, legal teams should start reassessing litigation strategies, particularly where expert testimony was excluded, to account for potential shifts in admissibility standards.
Disclosure protocols are also under review, with companies working to ensure that risk factors in public filings reflect emerging threats.
Financial resilience is being reinforced through stress testing reserves and insurance coverage, while proactive engagement with regulators is positioning companies to influence outcomes and demonstrate good-faith compliance.
As political rhetoric accelerates legal and regulatory shifts, companies across the healthcare sector must prepare for heightened scrutiny, evolving disclosure obligations and renewed litigation risks.